Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIN-CM
- Development stage
- Preclinical
- Lead developer
- Kintsugi Therapeutics
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
KIN-CM is a preclinical-stage small molecule Caspase-2 (CASP2) inhibitor being developed by Kintsugi Therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). Caspase-2 is a cysteine protease that plays a critical role in hepatocyte apoptosis, lipotoxicity, and endoplasmic reticulum (ER) stress-mediated lipogenesis, which are key drivers of NASH progression. By selectively inhibiting Caspase-2, KIN-CM aims to prevent hepatocyte cell death, reduce liver inflammation, and inhibit lipid accumulation, thereby halting or reversing the progression of liver fibrosis and steatohepatitis.
02
Targets
CASP2 (Caspase-2)
Beyond the preview
Go deeper on KIN-CM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIN-CM.